Actively Recruiting
A Study of DS3610a in Participants With Advanced Solid Tumor
Led by Daiichi Sankyo · Updated on 2025-12-10
70
Participants Needed
2
Research Sites
277 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.
CONDITIONS
Official Title
A Study of DS3610a in Participants With Advanced Solid Tumor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years of age or older at the time of consent
- Participants with relapsed, refractory, or intolerant advanced or metastatic solid tumors
- Willing and able to provide an adequate pretreatment or archival tumor tissue sample
- Measurable disease on CT or MRI imaging performed within 28 days before starting treatment
- Signed and dated informed consent form prior to any trial-specific procedures
You will not qualify if you...
- Inadequate washout period before starting treatment, including: major surgery within 4 weeks (or 2 weeks for low-invasive cases), curative radiation therapy within 4 weeks, chemotherapy/antibody/immunotherapy within 4 weeks, small molecules within 2 weeks or 5 half-lives, nitrosoureas within 6 weeks
- Known symptomatic central nervous system metastases, leptomeningeal disease, or cord compression (asymptomatic or treated CNS metastases allowed if neurologically stable)
- Uncontrolled or clinically significant cardiovascular disease, including myocardial infarction or unstable angina within 6 months, NYHA Class III or IV congestive heart failure, left ventricular ejection fraction ≤50%, or QTcF interval >470 ms
- History of cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic events within 6 months prior to enrollment
- Clinically severe lung problems requiring supplemental oxygen or related to serious pulmonary disorders or autoimmune diseases affecting the lungs, or prior pneumonectomy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
National Cancer Center Hospital
Chūōku, Japan, 104-0045
Actively Recruiting
2
National Cancer Center Hospital East
Kashiwa, Japan, 277-8577
Actively Recruiting
Research Team
C
Contact for Trial Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here